Suchergebnisse - "Nakajima, Yuto"

PubPharm (60)

1

Antithrombin exhibits anticoagulant effects on the emicizumab-based engineered bispecific antibody (NXT007)-mediated blood coagulation

enthalten in: Thrombosis research | 2024

von Nakajima, Y. | Ogiwara, K. | Inaba, K. | +2

2

Emicizumab-mediated hemostatic function assessed by thrombin generation assay in an in vitro model of factor VIII-depleted thrombophilia plasma

enthalten in: International journal of hematology | 2024

von Yada, K. | Ogiwara, K. | Shimonishi, N. | +4

3

Coagulation potentials of plasma-derived factors VIIa and X mixture (Byclot® ) evaluated by global coagulation assay in patients with acquired haemophilia A

enthalten in: Haemophilia : the official journal of the World Federation of Hemophilia | 2024

von Takeyama, M. | Furukawa, S. | Ogiwara, K. | +7

4

Hybrid human-porcine factor VIII proteins partially escape the inhibitory effects of anti-factor VIII inhibitor alloantibodies having A2 or C2 domain specificity

enthalten in: Haemophilia : the official journal of the World Federation of Hemophilia | 2024

von Mizumachi, K. | Nakajima, Y. | Shimonishi, N. | +4

5

The role of proteolytic cleavage at Arg336 and Arg372 of the A1 domain in factor VIIa/tissue factor-catalyzed reactions of B domain-deleted factor VIII

enthalten in: Biochimica et biophysica acta. General subjects | 2024

von Nakajima, Y. | Nogami, K.

6

NXT007-mediated hemostatic potential is suppressed by activated protein C-catalyzed inactivation of activated factor V

enthalten in: Research and practice in thrombosis and haemostasis | 2024

von Nakajima, Y. | Ogiwara, K. | Inaba, K. | +2

7

Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis

enthalten in: International journal of hematology | 2023

von Shimonishi, N. | Sasai, K. | Ogiwara, K. | +8

8

The spleen is the major site for the development and expansion of inhibitor producing-cells in hemophilia A mice upon FVIII infusion developing high-titer inhibitor

enthalten in: Thrombosis research | 2023

von Oda, A. | Furukawa, S. | Kitabatake, M. | +9

9

Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A

enthalten in: Pediatric blood & cancer | 2023

von Takeyama, M. | Matsumoto, N. | Abe, H. | +8

10

Impaired factor V-related anticoagulant mechanisms and deep vein thrombosis associated with A2086D and W1920R mutations

enthalten in: Blood advances | 2023

von Shimonishi, N. | Ogiwara, K. | Yoshida, J. | +5

1
2
3
4
5
6
Nächster »
[6]